Compare FWDI & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWDI | CTMX |
|---|---|---|
| Founded | 1961 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.4M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | FWDI | CTMX |
|---|---|---|
| Price | $7.02 | $5.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 730.1K | ★ 3.0M |
| Earning Date | 02-12-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | $18,187,525.00 | ★ $113,631,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $22.29 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.32 | $0.40 |
| 52 Week High | $46.00 | $6.15 |
| Indicator | FWDI | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 65.20 |
| Support Level | $7.08 | $5.26 |
| Resistance Level | $8.00 | $6.15 |
| Average True Range (ATR) | 0.56 | 0.42 |
| MACD | -0.06 | 0.10 |
| Stochastic Oscillator | 1.06 | 63.35 |
Forward Industries Inc is a provider of carrying and protective solutions. The company designs and distributes product protection for handheld electronic devices. Forward Industries sells soft-sided carrying cases for blood glucose diagnostic kits and portable consumer electronic devices such as tablets, personal computers, barcode Scanners, GPS devices, and others. The company operates in two segments, the OEM distribution segment sources and distributes carrying cases and other accessories for medical monitoring and diagnostic kits and a variety of other portable electronic and non-electronic devices directly to OEMs; The design segment, provides a full spectrum of hardware and software product design and engineering services. The majority of revenue is generated from the Design segment.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.